Drug Database · Clinicians

Ethambutol

Brands (10) Trabutol, Coxbutol, Ethambusaph-200…Show all

US brand (reference label): Ethambutol Hydrochloride; not a Philippine-registered brand.

Antituberculosis; Anti-tuberculosis; and others PH FDA category

Rx · Prescription drug13 PH productsPNF-listedPhilHealth GAMOTVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 3f6428d6-3745-4337-ad78-ebfff9f49135, version date May 5, 2026 (Ethambutol Hydrochloride · STI Pharma LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS ETHAMBUTOL HCl is indicated for the treatment of pulmonary tuberculosis.
US FDA label
Full indications and usage US FDA label

INDICATIONS ETHAMBUTOL HCl is indicated for the treatment of pulmonary tuberculosis. It should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. Selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in vitro susceptibility studies.

In patients who have not received previous antituberculous therapy, ie, initial treatment, the most frequently used regimens have been the following: ETHAMBUTOL HCl plus isoniazidETHAMBUTOL HCl plus isoniazid plus streptomycin. In patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent.

Consequently, in such retreatment patients, ETHAMBUTOL HCl should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. Antituberculous drugs used with ETHAMBUTOL HCl have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs.

Isoniazid, aminosalicylic acid, and streptomycin have also been used in multiple drug regimens. Alternating drug regimens have also been utilized.

Contraindications

CONTRAINDICATIONS ETHAMBUTOL HCl is contraindicated in patients who are known to be hypersensitive to this drug. It is also contraindicated in patients with known optic neuritis unless clinical judgment determines that it may be used. ETHAMBUTOL HCl is contraindicated in patients who are unable to appreciate and report visual side effects or changes in vision (e.g., young children, unconscious patients).

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE and ADMINISTRATION ETHAMBUTOL HCl should not be used alone, in initial treatment or in tretreatment. ETHAMBUTOL HCl should be administered on a once every 24-hour basis only. Absorption is not significantly altered by administration with food. Therapy, in general, should be continued until bacteriological conversion has become permanent and maximal clinical improvement has occurred.

ETHAMBUTOL HCl is not recommended for use in pediatric patients under thirteen years of age since safe conditions for use have not been established. Initial Treatment: In patients who have not received previous antituberculous therapy, administer ETHAMBUTOL HCl 15 mg/kg (7 mg/lb) of body weight, as a single oral dose once every 24 hours.

In the more recent studies, isoniazid has been administered concurrently in a single, daily, oral dose. Retreatment: In patients who have received previous antituberculous therapy, administer ETHAMBUTOL HCl 25 mg/kg (11 mg/lb) of body weight, as a single oral dose once every 24 hours. Concurrently administer at least one other antituberculous drug to which the organisms have been demonstrated to be susceptible by appropriate in vitro tests.

Suitable drugs usually consist of those not previously used in the treatment of the patient. After 60 days of ETHAMBUTOL HCl administration, decrease the dose to 15 mg/kg (7mg/lb) of body weight, and administer as a single oral dose once every 24 hours. During the period when a patient is on a daily dose of 25 mg/kg, monthly eye examinations are advised.

See Table for easy selection of proper weight-dose tablet(s). Weight-Dose Table 15 mg/kg (7 mg/lb) Schedule Weight Range Pounds Kilograms Dose In mg Under 85 lbs Under 37 Kg…………. ……………….500 85 – 94.5 37 – 43................. ……………….600 95 – 109.5 43 – 50................. ……………….700 110– 124.5 50 – 57................. ……………….800 125– 139.5 57 – 64................. ……………….900 140– 154.5 64 – 71................. ……………..1000 155– 169.5 71 – 79................. ……………..1100 170 – 184.5 79 – 84................. ……………..1200 185– 199.5 84 – 90................. ……………..1300 200– 214.5 90 – 97................. ……………..1400 215 and Over Over 97................ ……………..1500 25 mg/kg (11 mg/lb) Schedule Under 85 lbs.

Under 38 Kg............... ……………..900 85 – 92.5 38 – 42................. ……………..1000 93 – 101.5 42 – 45.5............... ……………..1100 102– 109.5 45.5 – 50............... ……………..1200 110 – 118.5 50 – 54................. ……………..1300 119 – 128.5 54 – 58................. ……………..1400 129 – 136.5 58 – 62................. ……………..1500 137 – 146.5 62 – 67................. ……………..1600 147 – 155.5 67 – 71................. ……………..1700 156 – 164.5 71 – 75................. ……………..1800 165– 173.5 75 – 79................. ……………..1900 174– 182.5 79 – 83................. ……………..2000 183– 191.5 83 – 87................. ……………..2100 192– 199.5 87 – 91................. ……………..2200 200– 209.5 91 – 95................. ……………..2300 210– 218.5 95 – 99................. ……………..2400 219 and Over Over 99................. ……………..2500

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

Pediatric Use ETHAMBUTOL HCl (ethambutol hydrochloride) is not recommended for use in pediatric patients under thirteen years of age since safe conditions for use have not been established.

Dosing: Older adult

Geriatric use (US label) US FDA label

Geriatric Use There are limited data on the use of ETHAMBUTOL HCl in the elderly. One study of 101 patients, 65 years and older, on multiple drug antituberculosis regimens included 94 patients on ETHAMBUTOL HCl. No differences in safety or tolerability were observed in these patients compared with that reported in adults in general. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Dosage forms

Philippines

  • Syrup: 200 mg per 5 mL, 200 mg/5 mL, 400 mg per 5 mL, 400 mg/5 mL
  • Tablet: 400 mg
  • Film-coated tablet: 400 mg

Registered products in the Philippines

13 products registered with the Food and Drug Administration (FDA) Philippines list Ethambutol as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products13
Philippine FDA-registered products for Ethambutol
Package insert
CoxbutolEthambutol Hydrochloride
400 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Huazhong Pharmaceutical Co., Ltd.China
AMB HK Enterprises Inc.
DRP-15677
Aug 20, 2029
Ethambusaph-200Ethambutol Hydrochloride
200 mg per 5 mL SyrupAmber Bottle with white aluminum cap x 60 mL and 120 mL (Box of 1's)
RxVAT-exempt
Azine Healthcare Pvt. Ltd.India
Ollen Pharma Trading Inc.
DRP-13765
Apr 13, 2028
Ethambusaph-400Ethambutol hydrochloride
400 mg per 5 mL SyrupAmber Bottle with white aluminum cap x 120 mL and 60 mL (Box of 1's)
RxVAT-exempt
Azine Healthcare Pvt. Ltd.India
Ollen Pharma Trading Inc.
DRP-13764
Apr 13, 2028
HambutolEthambutol Hydrochloride
400 mg TabletStrip foil x 10's (Box of 100's)
RxVAT-exempt
Drugmaker's Laboratories, Inc.Philippines
Drugmaker's Laboratories, Inc.
DRP-4434-03
Oct 7, 2027
NoneEthambutol Hydrochloride
400 mg TabletStrip foil x 10's Box of 100's
RxVAT-exempt
Drugmaker's Laboratories, Inc.Philippines
—
DRP-4434
Oct 7, 2027
NoneEthambutol Hydrochloride
400 mg TabletStrip foil x 10's Box of 100's
RxVAT-exempt
Drugmaker's Laboratories, Inc.Philippines
TGP Pharma Inc.
DRP-4434-01
Oct 7, 2027
PDR-400Ethambutol Hydrochloride
400 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 28 (Box of 672's)
RxVAT-exempt
Svizera Labs Private LimitedIndia
Ambica International Corporation
DRP-10745
Nov 17, 2026Past listed date
Saphetam-400Ethambutol hydrochloride
400 mg TabletAluminum Foil Strip x 10's (Box of 100's)
RxVAT-exempt
Sai Parenterals Ltd.India
Ollen Pharma Trading Inc.
DRP-14174
Dec 9, 2030
Saphetham-200Ethambutol Hydrochloride
200 mg per 5 mL SyrupAmber Bottle with white aluminum cap x 60 mL and 120 mL (Box of 1's)
RxVAT-exempt
Sai Parenterals Ltd.India
Ollen Pharma Trading Inc.
DRP-13770
Dec 11, 2030
Saphetham-400Ethambutol Hydrochloride
400 mg per 5 mL SyrupAmber Bottle with white aluminum cap x 60 mL and 120 mL (Box of 1's)
RxVAT-exempt
Sai Parenterals Ltd.India
Ollen Pharma Trading Inc.
DRP-13769
Dec 11, 2030
TambutolEthambutol Hydrochloride
400 mg TabletStrip Foil x 10's (Box of 100's)
RxVAT-exempt
Drugmaker's Laboratories, Inc.Philippines
TGP Pharma Inc.
DRP-4434-02
Oct 7, 2027
TrabutolEthambutol hydrochloride
200mg/5mL SyrupBoston Round amber bottle x 15mL Box of 1's; Boston Round amber bottle x 60mL Box of 1's; Boston Round amber bottle x 120mL Box of 1's
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Natrapharm,Inc.
DR-XY43625
Aug 13, 2029
TrabutolEthambutol hydrochloride
400 mg/5 mL SyrupBoston Round Amber Bottle x 15 mL (Box of 1's); Boston Round Amber Bottle x 60 mL (Box of 1's); Boston Round Amber Bottle x 120 mL (Box of 1's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Natrapharm, Inc.
DR-XY43624
Aug 13, 2029

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS ETHAMBUTOL HCl may produce decreases in visual acuity which appear to be due to optic neuritis. This effect may be related to dose and duration of treatment. This effect is generally reversible when administration of the drug is discontinued promptly. However, irreversible blindness has been reported. (See PRECAUTIONS and ADVERSE REACTIONS). Liver toxicities including fatalities have been reported (see ADVERSE REACTIONS). Baseline and periodic assessment of hepatic function should be performed.

Drug interactions

Drug interactions (US label) US FDA label

Drug Interactions The results of a study of coadministration of ETHAMBUTOL HCl (50mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products. It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS ETHAMBUTOL HCl may produce decreases in visual acuity, including irreversible blindness, which appear to be due to optic neuritis. Optic neuropathy including optic neuritis or retrobulbar neuritis occurring in association with ethambutol therapy may be characterized by one or more of the following events: decreased visual acuity, scotoma, color blindness, and/or visual defect.

These events have also been reported in the absence of a diagnosis of optic or retrobulbar neuritis. Patients should be advised to report promptly to their physician any change of visual acuity. The change in visual acuity may be unilateral or bilateral and hence each eye must be tested separately and both eyes tested together.

Testing of visual acuity should be performed before beginning ETHAMBUTOL HCl therapy and periodically during drug administration, except that it should be done monthly when a patient is on a dosage of more than 15 mg per kilogram per day. Snellen eye charts are recommended for testing of visual acuity. Studies have shown that there are definite fluctuations of one or two lines of the Snellen chart in the visual acuity of many tuberculous patients not receiving ETHAMBUTOL HCl.

The following table may be useful in interpreting possible changes in visual acuity attributable to ETHAMBUTOL HCl. Initial Reading Significant Decreased Snellen Indicating Number Number Reading Significant of Lines of Points Decrease 20/13 20/25 3 12 20/15 20/25 2 10 20/20 20/30 2 10 20/25 20/40 2 15 20/30 20/50 2 20 20/40 20/70 2 30 20/50 20/70 1 20 In general, changes in visual acuity less than those indicated under “Significant Number of Lines” and “Decrease Number of Points” may be due to chance variation, limitations of the testing method, or physiologic variability.

Conversely, changes in visual acuity equaling or exceeding those under “Significant Number of Lines” and “Decrease Number of Points” indicate need for retesting and careful evaluation of the patient's visual status. If careful evaluation confirms the magnitude of visual change and fails to reveal another cause, ETHAMBUTOL HCl should be discontinued and the patient reevaluated at frequent intervals.

Progressive decreases in visual acuity during therapy must be considered to be due to ETHAMBUTOL HCl. If corrective glasses are used prior to treatment, these must be worn during visual acuity testing. During 1 to 2 years of therapy, a refractive error may develop which must be corrected in order to obtain accurate test results.

Testing the visual acuity through a pinhole eliminates refractive error. Patients developing visual abnormality during ETHAMBUTOL HCl treatment may show subjective visual symptoms before, or simultaneously with, the demonstration of decreases in visual acuity, and all patients receiving ETHAMBUTOL HCl should be questioned periodically about blurred vision and other subjective eye symptoms.

Recovery of visual acuity generally occurs over a period of weeks to months after the drug has been discontinued. Some patients have received ETHAMBUTOL HCl (ethambutol hydrochloride) again after such recovery without recurrence of loss of visual acuity. Other adverse reactions reported include: hypersensitivity, anaphylactic/anaphylactoid reaction, dermatitis, erythema multiforme, pruritus, and joint pain; anorexia, nausea, vomiting, gastrointestinal upset, and abdominal pain; fever, malaise, headache, and dizziness; mental confusion, disorientation, and possible hallucinations; thrombocytopenia, leucopenia, and neutropenia.

Numbness and tingling of the extremities due to peripheral neuritis have been reported. Elevated serum uric acid levels occur and precipitation of acute gout has been reported. Pulmonary infiltrates, with or without eosinophilia, also have been reported during ETHAMBUTOL HCl therapy. Liver toxicities, including fatalities, have been reported.

(See WARNINGS). Since ETHAMBUTOL HCl is recommended for therapy in conjunction with one or more other antituberculous drugs, these changes may be related to the concurrent therapy. Hypersensitivity syndrome consisting of cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, and one or more of the following: hepatitis, pneumonitis, nephritis, myocarditis, pericarditis.

Fever and lymphadenopathy may be present.

Adverse reaction frequency tables (US label) US FDA label
InitialReadingSignificantDecreased
SnellenIndicatingNumberNumber
ReadingSignificantof Linesof Points
Decrease
20/1320/25312
20/1520/25210
20/2020/30210
20/2520/40215
20/3020/50220
20/4020/70230
20/5020/70120

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy Teratogenic Effects: Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. There are reports of ophthalmic abnormalities occurring in infants born to women on antituberculous therapy that included ETHAMBUTOL HCl. ETHAMBUTOL HCl should be used during pregnancy only if the benefit justifies the potential risk to the fetus.

ETHAMBUTOL HCl has been shown to be teratogenic in pregnant mice and rabbits when given in high doses. When pregnant mice or rabbits were treated with high doses of ethambutol hydrochloride, fetal mortality was slightly but not significantly (P>0.05) increased. Female rats treated with ethambutol hydrochloride displayed slight but insignificant (P>0.05) decreases in fertility and litter size.

In fetuses born of mice treated with high doses of ETHAMBUTOL HCl during pregnancy, a low incidence of cleft palate, exencephaly and abnormality of the vertebral column were observed. Minor abnormalities of the cervical vertebra were seen in the newborn of rats treated with high doses of ethambutol hydrochloride during pregnancy.

Rabbits receiving high doses of ETHAMBUTOL HCl during pregnancy gave birth to two fetuses with monophthalmia, one with a shortened right forearm accompanied by bilateral wristjoint contracture and one with hare lip and cleft palate.

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers ETHAMBUTOL HCl is excreted into breast milk. The use of ETHAMBUTOL HCl should be considered only if the expected benefit to the mother outweighs the potential risk to the infant.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

During the 24-hour period following oral administration of ETHAMBUTOL HCl approximately 50 percent of the initial dose is excreted unchanged in the urine, while an additional 8 to 15 percent appears in the form of metabolites.

From 20 to 22 percent of the initial dose is excreted in the feces as unchanged drug.

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY ETHAMBUTOL HCL, following a single oral dose of 25 mg/kg of body weight, attains a peak of 2 to 5 mcg/mL in serum 2 to 4 hours after administration. When the drug is administered daily for longer periods of time at this dose, serum levels are similar. The serum level of ETHAMBUTOL HCL falls to undetectable levels by 24 hours after the last dose except in some patients with abnormal renal function.

The intracellular concentrations of erythrocytes reach peak values approximately twice those of plasma and maintain this ratio throughout the 24 hours. During the 24-hour period following oral administration of ETHAMBUTOL HCl approximately 50 percent of the initial dose is excreted unchanged in the urine, while an additional 8 to 15 percent appears in the form of metabolites.

The main path of metabolism appears to be an initial oxidation of the alcohol to an aldehydic intermediate, followed by conversion to a dicarboxylic acid. From 20 to 22 percent of the initial dose is excreted in the feces as unchanged drug. No drug accumulation has been observed with consecutive single daily doses of 25 mg/kg in patients with normal kidney function, although marked accumulation has been demonstrated in patients with renal insufficiency.

ETHAMBUTOL HCl diffuses into actively growing Mycobacterium cells such as tubercle bacilli. ETHAMBUTOL HCl appears to inhibit the synthesis of one or more metabolites, thus causing impairment of cell metabolism, arrest of multiplication, and cell death. No cross resistance with other available antimycobacterial agents has been demonstrated.

ETHAMBUTOL HCl has been shown to be effective against strains of Mycobacterium tuberculosis but does not seem to be active against fungi, viruses, or other bacteria. Mycobacterium tuberculosis strains previously unexposed to ETHAMBUTOL HCL have been uniformly sensitive to concentrations of 8 or less mcg/mL, depending on the nature of the culture media.

When ETHAMBUTOL HCl has been used alone for treatment of tuberculosis, tubercle bacilli from these patients have developed resistance to ETHAMBUTOL HCl (ethambutol hydrochloride) by in vitro susceptibility tests; the development of resistance has been unpredictable and appears to occur in a step-like manner. No cross resistance between ETHAMBUTOL HCl and other antituberculous drugs has been reported.

ETHAMBUTOL HCl has reduced the incidence of the emergence of mycobacterial resistance to isoniazid when both drugs have been used concurrently. An agar diffusion microbiologic assay, based upon inhibition of Mycobacterium smegmatis (ATCC 607) may be used to determine concentrations of ETHAMBUTOL HCl in serum and urine.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Ethambutol Hydrochloride 400 mg Tablet₱2.99–₱3.50Reference ₱2.99per tabletDPRI procurement range
100 mg (as hydrochloride) tablet (pediatric)₱4.25per tabletPhilHealth GAMOT fixed fee
200 mg (as hydrochloride) tablet₱4.25per tabletPhilHealth GAMOT fixed fee
400 mg (as hydrochloride) tablet₱5.00per tabletPhilHealth GAMOT fixed fee

PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Ethambutol (as hydrochloride)
PNF listingOral: 100 mg tablet (pediatric)
PNF listingOral: 200 mg and 400 mg tablet
PhilHealth GAMOTYes (listed since October 13, 2026)

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Ethambutol Hydrochloride · STI Pharma LLC [US FDA-approved label, version 9, May 5, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f6428d6-3745-4337-ad78-ebfff9f49135
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  5. PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  6. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .